Biotechnology is the exploitation of living systems or molecules from them for commercial gain. Although the word 'biotechnology' is only a few decades old, humankind has been using biotechnology for ...

However, the biotech has what it takes to be successful in the challenging gene-editing niche. This company might be worth far more than many realize. If I had to buy one share of any biotech with ...

Body Dimensions 164.5 x 75 x 7.9 mm (6.48 x 2.95 x 0.31 in) ...

The last update introduced players to Caesar King and the Sons of Calydon as they navigate New Eridu’s outer ring to survive. Now, players meet a new member of the Sons of Calydon, along with a proper ...

The Zenless Zone Zero 1.3 banners introduce two dynamic agents, each embodying opposing forces in New Eridu. Unveiled during the Virtual Revenge livestream, the spotlight landed on new playable ...

Zenless Zone Zero update 1.3 is ripe with events and new game modes, bringing two permanent additions to the game alongside a host of time-limited content and fresh locations. Both new Agents ...

Have you ever considered what would’ve happened to Bill Murray’s character in Groundhog Day if he hadn’t got out of that time loop? If he’d just stayed living the same day over, and over ...

There are plenty of intriguing Zenless Zone Zero characters to meet in Hoyoverse’s exciting, upcoming game, with more popping up all the time. So, to keep you up to date as you prepare to dive into ...

However, it's important to remember that this is still a pre-revenue biotech stock. The company has $154 million in cash, equivalents, and short-term investments as of the second quarter ...

EF Hutton initiated coverage on ImmunityBio (IBRX) with a Buy rating and a $30 price target. ImmunityBio's Anktiva shows high complete response rates in trials, enhancing immunotherapy for BCG ...

Eye drug maker Ocuphire Pharma is acquiring gene therapy developer Opus Genetics in an all-stock transaction that will see the commercial-stage company adopt the biotech’s identity. The ...

EF Hutton has initiated coverage on ImmunityBio Inc. (NASDAQ:IBRX), a vertically integrated biotechnology company developing therapies and vaccines to bolster the natural immune system for cancers ...